AstraZeneca
dual and receptor agonist promising efficacy in overweight patients with fatty liver | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
40 of 86
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
April 2023
peace phase trial mobility assessed by and | Aeglea BioTherapeutics
MindMed
Investor Presentation
December 2024
for phase study design design | MindMed
Aeglea BioTherapeutics
Investor Presentation
May 2023
peace phase trial mobility assessed by and | Aeglea BioTherapeutics
MindMed
Investor Presentation
January 2025
robust phase development program aiming for broad label | MindMed
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights